Having completed a first phase of hypothesis-driven research and a second phase of Omics big-data methods, TRTOI is advancing toward a next stage centered on AI-driven analysis.
Research Frontiers
- Epitranscriptome (m6A): exploring how RNA methylation worsens chronic kidney disease and seeking actionable therapeutic targets.
- Epigenome: studying DNA methylation (5mC) and the regulation of writers (DNMTs) and erasers (TETs) in kidney disease.
- Long-read sequencing: incorporated into TRTOI to study alternative splicing in kidney disease.
- AI computing: linking ultrasound imaging, electronic health records and omics data to develop risk prediction and non-invasive biomarkers.
TRTOI will expand its governance framework, adopt the latest assay methods and reach advance toward kidney precision medicine.